Adam Feuerstein✡️
Reporter at STAT. The Harry Kane of biotech. Dog ❤️er. Polk Award winner. Said one analyst: The likes of Adam Feuerstein attack viciously.
- Follow me on X. This site has become unbearable.
- Reposted by Adam Feuerstein✡️So @statnews.com has had a LOT of coverage of the ouster of the FDA's Peter Marks. The news: statnews.com/2025/03/28/f... Analysis from @adamfeuerstein.bsky.social statnews.com/2025/03/30/f... Analysis from @matthewherper.bsky.social statnews.com/2025/03/31/r...
- FDA’s ‘key man’ Peter Marks is out. Biotech investors will now deal with the consequences www.statnews.com/2025/03/30/f...
- RFK Jr. misleads, deceives or simply lies when he claims the measles vaccine "routinely" causes deaths. IT DOES NOT. @matthewherper.bsky.social lays out the facts. www.statnews.com/2025/03/14/r...
- The Senate confirmation hearing for FDA Commissioner nominee Marty Makary is scheduled to start at 10 am ET. STAT's live blog is here for those who want to check in during the day: www.statnews.com/2025/03/06/m...
- How to eliminate biotech zombies: Buy them www.statnews.com/2025/02/27/b...
- Pfizer CEO Albert Bourla inflicts injury on his company — and all of pharma The hiring of a former top FDA official amplifies ‘revolving door’ criticism at the worst possible time www.statnews.com/2025/02/24/p...
- Trump administration rehires some FDA employees it fired www.statnews.com/2025/02/23/f... via @lizzylawrence.bsky.social
- A race to the bottom — too much weight loss? A new, must-read story from my colleague @elaineywchen.bsky.social Patients in trials of Eli Lilly's next-gen obesity drug think they're losing too much weight. One started skipping doses, another is making himself eat caloric foods. Link below...
- New obesity treatments have been transformational, but the fixation on more weight loss may not be in patients' best interests, doctors say. But rapid and extreme weight loss may lead to too much muscle loss, a weakened immune system, and other risks. www.statnews.com/2025/02/20/t...
- This week's Biotech Scorecard newsletter: Why biotech’s future is threatened by zombies (Not the movie kind, the money-wasting, space-sucking negative enterprise value kind!) www.statnews.com/2025/02/20/w...
- You absolutely must read this interview: FDA’s former top food official says Trump firings are ‘dismantling’ the division In candid interview, Jim Jones says moves will undercut RFK Jr.’s agenda www.statnews.com/2025/02/18/f... via @matthewherper.bsky.social
- Biogen $BIIB partners with Stoke Therapeutics $STOK on drug for severe epilepsy www.statnews.com/2025/02/18/b...
- Duchenne gene therapy from Solid Biosciences $SLDB produces promising results in early study www.statnews.com/2025/02/18/s... via @jasonmast.bsky.social $RGRX $SRPT
- Drug inspectors, AI experts, maternal health workers: Trump’s health agency cuts are far-reaching In interviews w/ STAT, those who were fired, along with officials who remain, argued the cuts would be deeply felt. www.statnews.com/2025/02/17/t... via @helenbranswell.bsky.social
- Trump administration lays off FDA employees www.statnews.com/2025/02/15/t... via @statnews.com
- Remember the heroic Kate Winslet character in the movie Contagion? Well, they just fired the Kate Winslets... CDC cuts expected to devastate Epidemic Intelligence Service, a ‘crown jewel’ of public health www.statnews.com/2025/02/14/t... via @helenbranswell.bsky.social
- A reminder that I can be reached on Signal at stafaf.54
- BREAKING: Trump administration to fire thousands at health agencies www.statnews.com/2025/02/14/f... via @statnews.com
- Biotech is in a dark place. The market offers one beatdown after another. Sentiment is lousy and the bad mood is relentless, to the point where people are seriously wondering if a sector turnaround is ever possible. Sorry, but it's just depressing out there... www.statnews.com/2025/02/13/b...
- As outcry builds over Trump cuts to NIH payments, drugmakers are MIA On last night's earnings call, $VRTX CEO Reshma Kewalramani said nothing about the NIH, yet Vertex owes some of that $11B in cystic fibrosis drug sales to foundational biomedical research funded by NIH....
- She's not alone.. The silence from biotech and pharma CEOs — $AMGN $LLY $REGN $GILD — is (to use a cliché) deafening. Read the story here: www.statnews.com/2025/02/11/n...
- $ABSI and Generate Biomedicines say they’re using AI to conjure drugs from scratch. Documents, experts suggest otherwise www.statnews.com/2025/02/10/a... via @brittanytrang.bsky.social
- The CRISPR companies are not OK Today, in @statnews.com - a must-read story from my colleague @jasonmast.bsky.social www.statnews.com/2025/02/06/c...
- Layoffs have hit nearly every CRISPR company — large and small. Stock prices have plunged. Pipelines have been pared back. Remember Casgevy, the heralded "first CRISPR medicine?" Well, only a tiny handful of sickle cell patients have been treated with it...
- For several months, @jasonmast.bsky.social embedded himself inside CRISPR world, interviewing scientists, company executives and analysts to get a clearer picture of why this once-brazen field has been humbled, and what can be done to turn it around. Read: www.statnews.com/2025/02/06/c...
- Austin Leclaire was a remarkable young man with Duchenne who raised awareness about his devastating disease, and as a patient advocate, played a pivotal role in spurring the development of the first medicines to treat it. Austin died on Feb. 1. He was 26. www.statnews.com/2025/02/06/a...
- Personalized cancer vaccine shows potential in kidney cancer www.statnews.com/2025/02/05/p... via @statnews.com
- VACCINES DO NOT CAUSE AUTISM. (Yes, I'm typing in my loud voice.) @matthewherper.bsky.social lays out the facts. www.statnews.com/2025/02/03/v...
- Vertex wins FDA approval for non-opioid pain drug, setting stage for closely watched rollout www.statnews.com/2025/01/30/v... via @jonathanwosen.bsky.social
- In this week's Biotech Scorecard newsletter: MASH drugs have reached a meaningful tipping point for patients and investors. $MDGL already topping $400 million in annualized sales. $AKRO reversing cirrhosis in F4 patients + $ETNB following ...
- It's taken a long time — a lot of ups and downs — but MASH is finally proving to be a massive opportunity. Really good to see. You can read a web version of my newsletter here: www.statnews.com/2025/01/30/m...
- f you're a STAT subscriber and wish to receive my Biotech Scorecard newsletter in your inbox every Thursday morning, please sign up here: www.statnews.com/signup/score...
- The 7 big topics RFK Jr. addressed during a fiery confirmation hearing www.statnews.com/2025/01/29/r... via @statnews.com
- Hey folks -- STAT will be covering tomorrow's RFK Jr. confirmation hearing with a live blog run by our indefatigable DC correspondents. Stay tuned tomorrow morning for a link. Thank you!
- FDA cancellation of the Feb. 25 adcomm for Novartis' drug Fabhalta is NOT Trump related, Novartis told me. FDA decided adcomm wasn't needed to complete the drug review.
- RFK Jr. says he doesn’t want to take away vaccines — he just wants to make sure they’re safe. But he's already sketched out a blueprint that could subject recommended vaccines to renewed scrutiny, redirect research, strip legal protections, and change how vaccines are advertised.
- As confirmation hearings get ready to start, @statnews.com news reporters Sarah Owermohle and Rachel Cohrs Zhang examine how RFK Jr. might use the levers of power as the top U.S. health official to sow doubt about vaccines at a time when rates of childhood immunizations are already slipping.
- Read their reporting on RFK Jr. here: RFK Jr.’s step-by-step blueprint to question the safety of vaccines www.statnews.com/2025/01/28/r...
- Daiichi Sankyo AstraZeneca — Enhertu expanded FDA approval covering “ultra low” HER2 expression www.astrazeneca.com/media-centre...
- From a market cap perspective, the massive drop today in NVDA’s stock price was roughly equivalent to four Pfizers. Amazing.
- To put these new $AKRO data into context, patients w/ cirrhosis due to MASH have a severe form of disease w/ few treatment options outside of liver transplant. Once MASH progresses to cirrhosis, median survival is about 5 years, three times shorter than for patients with moderate MASH.
- GLP-1s don't help these patients. $MDGL 's Rezdiffra is prescribed mostly for patients with early and moderate MASH. $ETNB is developing a drug similar to $AKRO. Stock up 66% pre market. www.statnews.com/2025/01/27/a...
- Akero $AKRO drug reverses liver scarring in study of severe MASH patients www.statnews.com/2025/01/27/a...
- The FDA remains open, despite some of the bad information you may have seen/read. www.prnewswire.com/news-release...
